Navigation Links
China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes
Date:9/1/2009

of cactus-derived products, including nutraceuticals, nutritious food, health and energy drinks, beer, wine and liquor, extracts and powders, and animal feed. China Kangtai controls over 387 acres of plants and maintains an active R&D group that holds 18 product patents and is seeking another 12. China Kangtai's high-quality "green" products are sold throughout China via a distribution network that covers 12 of China's 23 provinces and two of China's four municipalities. More information may be found at http://www.biocactus.com or via e-mail: chinakangtai@gmail.com.

An investment profile on China Kangtai Cactus Biotech Inc. is available at http://www.hawkassociates.com/profile/ckgt.cfm . For an online investor relations kit, visit http://www.hawkassociates.com . For more investor-related questions, contact Susan Zhou, Hawk Associates, at 305-451-1888, e-mail: cactus@hawkassociates.com. To subscribe to future releases via e-mail alert, visit http://www.hawkassociates.com/about/alert/ .

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. F
'/>"/>

SOURCE China Kangtai Cactus Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
2. AOBOs Products Included in Chinas Essential Drug List
3. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
4. China Medical Technologies to Announce Unaudited Financial Results for the Fourth Fiscal Quarter and Fiscal Year ended March 31, 2009 and the First Fiscal Quarter ended June 30, 2009 on September 1, 2009
5. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
6. China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results
7. China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results
8. China Biologic Products Schedules 2009 Second Quarter Earnings Conference Call
9. Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2009 Results
11. China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014  LABSCO, the leading specialty sales ... hospitals, physician office laboratories and alternate healthcare settings ... 2014, it will serve as Siemens Healthcare Diagnostics, ... and as a semi-exclusive sales distributor in specified ... United States . LABSCO will be ...
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  The full interim results will be ... GRS and IGF Society, being held October 15-18, ...
(Date:9/16/2014)... BCC Research reveals in its ... , the global market for stem cells is expected ... a five-year compound annual growth rate (CAGR) of 13.6%. ... with growth projections of $2.2 billion in 2014 to ... , Unlike other potential applications of bioscience, ...
(Date:9/16/2014)... RENU 28, the world's first and only skin gel ... in Australia and New Zealand in mid-August . , The ... tour will make stops in Brisbane on September 16, the ... on the 20th, and Melbourne on the 22nd. , Helping ... to educate people about the new product and business opportunity ...
Breaking Biology Technology:LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2
... EDMONTON, June 2 /PRNewswire-FirstCall/ - Quest PharmaTech ... that its 12-patient,Phase I clinical study entitled "ACP-SL017 ... Therapy of Actinic Keratosis" has met both its ... have received, for the first time, clinical,validation for ...
... 2 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a,company ... early,detection of diseases and personalized health management, today ... Company,s first,product, ColonSentry(TM)., Effective May 31, 2008, ... CEO to take on new duties as Chief ...
... genetic mutations that can affect patient response to ... ... DxS Ltd. have,signed an exclusive distribution agreement for the DxS TheraScreen ... when considered with other clinically relevant factors, to aid,doctors in identifying ...
Cached Biology Technology:Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 3GeneNews announces management changes to support commercialization of ColonSentry(TM) 2Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests 2Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests 3
(Date:9/16/2014)... Each tree species has its own bacterial identity. That,s ... from other institutions who studied the genetic fingerprints of ... Panamanian island. , "This study demonstrates for the first ... with different ecological strategies possess very different microbial communities ... a former postdoctoral researcher in the UO,s Institute of ...
(Date:9/16/2014)... chunk of rock hit the Yukatan peninsula near the site ... 100 teratons of TNT. It left a crater more than ... and volcanism are widely accepted to have wiped out the ... But what happened to the plants on which the dinosaurs ... University of Arizona reveals that the meteorite impact that spelled ...
(Date:9/16/2014)... complex web of interaction between viruses, bacteria, and ... a growing international collaboration between Matthew Sullivan, associate ... Ecology and Evolutionary Biology and Steven Hallam from ... , "Bacteria are drivers of nutrient and ... "As the climate is changing, so are the ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3
... small number of households could go a long way to ... measured differences in energy demands at the household level, appears ... Dominik Saner and colleagues point out that the energy ... mobility needs accounts for more than 70 percent of emissions ...
... accurately, according to a new study by the late ... in Germany. Their analysis of human melody singing in ... work is published online in Springer,s journal Animal ... one of the most complex and demanding cognitive challenges ...
... Down syndrome, more commonly known as "trisomy 21" is ... population: Alzheimer,s disease, leukemia, or cardiac deficiency. In a ... Faculty of Medicine of the University of Geneva (UNIGE), ... 21, determining the risk of congenital heart disease in ...
Cached Biology News:Songbirds turn on and tune up 2Complex genetic architectures: Some common symptoms of trisomy 21 2
Goat polyclonal to Duffy / FY / DARC...
SMVT (N-14)...
... Description: Proteinase K is a ... wide range of applications purified from the fungus ... the carboxyl group of N-substituted hydrophobic aliphatic and ... as a serine protease. Proteinase K is useful ...
... The H2OBIT™ is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
Biology Products: